Adenovirus- and cytomegalovirus-specific adoptive T-cell therapy in the context of hematologic cell transplan or HIV infection - A single-center experience.
adenovirus
adoptive immunotherapy
cytomegalovirus
virus‐specific T‐cells
Journal
Transplant infectious disease : an official journal of the Transplantation Society
ISSN: 1399-3062
Titre abrégé: Transpl Infect Dis
Pays: Denmark
ID NLM: 100883688
Informations de publication
Date de publication:
03 Jun 2024
03 Jun 2024
Historique:
revised:
17
04
2024
received:
14
02
2024
accepted:
05
05
2024
medline:
4
6
2024
pubmed:
4
6
2024
entrez:
3
6
2024
Statut:
aheadofprint
Résumé
Reactivation of viral infections, in particular cytomegalovirus (CMV) and adenovirus (ADV), cause morbidity and non-relapse-mortality in states of immune deficiency, especially after allogeneic hematopoietic cell transplantation (allo-HCT). Against the background of few available pharmacologic antiviral agents, limited by toxicities and resistance, adoptive transfer of virus-specific T-cells (VST) is a promising therapeutic approach. We conducted a single-center retrospective analysis of adult patients treated with ADV- or CMV-specific T-cells in 2012-2022. Information was retrieved by review of electronic health records. Primary outcome was a response to VST by decreasing viral load or clinical improvement. Secondary outcomes included overall survival and safety of VST infusion, in particular association with graft-versus-host disease (GVHD). Ten patients were included, of whom four were treated for ADV, five for CMV, and one for ADV-CMV-coinfection. Cells were derived from stem cell donors (6/10) or third-party donors (4/10). Response criteria were met by six of 10 patients (4/4 ADV, 2/5 CMV, and 0/1 ADV-CMV). Overall survival was 40%. No infusion related adverse events were documented. Aggravation of GVHD after adoptive immunotherapy was observed in two cases, however in temporal association with a conventional donor lymphocyte infusion and a stem cell boost, respectively. In this cohort, CMV- and ADV-specific T-cell therapy appear to be safe and effective. We describe the first reported case of virus-specific T-cell therapy for CMV reactivation not associated with transplantation but with advanced HIV infection. This encourages further evaluation of adoptive immunotherapy beyond the context of allo-HCT.
Sections du résumé
BACKGROUND
BACKGROUND
Reactivation of viral infections, in particular cytomegalovirus (CMV) and adenovirus (ADV), cause morbidity and non-relapse-mortality in states of immune deficiency, especially after allogeneic hematopoietic cell transplantation (allo-HCT). Against the background of few available pharmacologic antiviral agents, limited by toxicities and resistance, adoptive transfer of virus-specific T-cells (VST) is a promising therapeutic approach.
METHODS
METHODS
We conducted a single-center retrospective analysis of adult patients treated with ADV- or CMV-specific T-cells in 2012-2022. Information was retrieved by review of electronic health records. Primary outcome was a response to VST by decreasing viral load or clinical improvement. Secondary outcomes included overall survival and safety of VST infusion, in particular association with graft-versus-host disease (GVHD).
RESULTS
RESULTS
Ten patients were included, of whom four were treated for ADV, five for CMV, and one for ADV-CMV-coinfection. Cells were derived from stem cell donors (6/10) or third-party donors (4/10). Response criteria were met by six of 10 patients (4/4 ADV, 2/5 CMV, and 0/1 ADV-CMV). Overall survival was 40%. No infusion related adverse events were documented. Aggravation of GVHD after adoptive immunotherapy was observed in two cases, however in temporal association with a conventional donor lymphocyte infusion and a stem cell boost, respectively.
CONCLUSION
CONCLUSIONS
In this cohort, CMV- and ADV-specific T-cell therapy appear to be safe and effective. We describe the first reported case of virus-specific T-cell therapy for CMV reactivation not associated with transplantation but with advanced HIV infection. This encourages further evaluation of adoptive immunotherapy beyond the context of allo-HCT.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14296Informations de copyright
© 2024 The Author(s). Transplant Infectious Disease published by Wiley Periodicals LLC.
Références
Green ML, Leisenring W, Xie H, et al. Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre‐emptive therapy: a retrospective cohort study. Lancet Haematol. 2016;3(3):e119‐e127. doi:10.1016/S2352‐3026(15)00289‐6
Hill JA, Mayer BT, Xie H, et al. The cumulative burden of double‐stranded DNA virus detection after allogeneic HCT is associated with increased mortality. Blood. 2017;129(16):2316‐2325. doi:10.1182/blood‐2016‐10‐748426
Teira P, Battiwalla M, Ramanathan M, et al. Early cytomegalovirus reactivation remains associated with increased transplant‐related mortality in the current era: a CIBMTR analysis. Blood. 2016;127(20):2427‐2438. doi:10.1182/blood‐2015‐11‐679639
Lion T. Adenovirus infections in immunocompetent and immunocompromised patients. Clin Microbiol Rev. 2014;27(3):441‐462. doi:10.1128/CMR.00116‐13
Marty FM, Ljungman P, Chemaly RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic‐cell transplantation. N Engl J Med. 2017;377(25):2433‐2444. doi:10.1056/NEJMoa1706640
Avery RK, Alain S, Alexander BD, et al. Maribavir for refractory cytomegalovirus infections with or without resistance post‐transplant: results from a Phase 3 randomized clinical trial. Clin Infect Dis. 2022;75(4):690‐701. doi:10.1093/cid/ciab988
Chou S, Alain S, Cervera C, et al. Drug resistance assessed in a Phase 3 clinical trial of maribavir therapy for refractory or resistant cytomegalovirus infection in transplant recipients. J Infect Dis. 2023. doi:10.1093/infdis/jiad293
Chou S, Kleiboeker S. Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. Antiviral Res. 2022;207:105422. doi:10.1016/j.antiviral.2022.105422
Kleiboeker SB. Prevalence of cytomegalovirus antiviral drug resistance in transplant recipients. Antiviral Res. 2023;215:105623. doi:10.1016/j.antiviral.2023.105623
Jacobsen T, Sifontis N. Drug interactions and toxicities associated with the antiviral management of cytomegalovirus infection. Am J Health Syst Pharm. 2010;67(17):1417‐1425. doi:10.2146/ajhp090424
Camargo JF, Wieder ED, Kimble E, et al. Deep functional immunophenotyping predicts risk of cytomegalovirus reactivation after hematopoietic cell transplantation. Blood. 2019;133(8):867‐877. doi:10.1182/blood‐2018‐10‐878918
Zandvliet ML, Falkenburg JH, van Liempt E, et al. Combined CD8+ and CD4+ adenovirus hexon‐specific T cells associated with viral clearance after stem cell transplantation as treatment for adenovirus infection. Haematologica. 2010;95(11):1943‐1951. doi:10.3324/haematol.2010.022947
Feuchtinger T, Lucke J, Hamprecht K, et al. Detection of adenovirus‐specific T cells in children with adenovirus infection after allogeneic stem cell transplantation. Br J Haematol. 2005;128(4):503‐509. doi:10.1111/j.1365‐2141.2004.05331.x
Stern L, McGuire HM, Avdic S, et al. Immunoprofiling reveals cell subsets associated with the trajectory of cytomegalovirus reactivation post stem cell transplantation. Nat Commun. 2022;13(1):2603. doi:10.1038/s41467‐022‐29943‐9
Papadopoulou A, Alvanou M, Karavalakis G, Tzannou I, Yannaki E. Pathogen‐specific T cells: targeting old enemies and new invaders in transplantation and beyond. Hemasphere. 2023;7(1):e809. doi:10.1097/HS9.0000000000000809
Walti CS, Stuehler C, Palianina D, Khanna N. Immunocompromised host section: adoptive T‐cell therapy for dsDNA viruses in allogeneic hematopoietic cell transplant recipients. Curr Opin Infect Dis. 2022;35(4):302‐311. doi:10.1097/QCO.0000000000000838
Feuchtinger T, Opherk K, Bethge WA, et al. Adoptive transfer of pp65‐specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood. 2010;116(20):4360‐4367. doi:10.1182/blood‐2010‐01‐262089
Feucht J, Opherk K, Lang P, et al. Adoptive T‐cell therapy with hexon‐specific Th1 cells as a treatment of refractory adenovirus infection after HSCT. Blood. 2015;125(12):1986‐1994. doi:10.1182/blood‐2014‐06‐573725
Heinz AT, Calkoen FGJ, Derbich A, et al. Automated production of specific T cells for treatment of refractory viral infections after allogeneic stem cell transplantation. Haematologica. 2023;108(8):2080‐2090. doi:10.3324/haematol.2022.281996
Icheva V, Kayser S, Wolff D, et al. Adoptive transfer of epstein‐barr virus (EBV) nuclear antigen 1‐specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem‐cell transplantation. J Clin Oncol. 2013;31(1):39‐48. doi:10.1200/JCO.2011.39.8495
Kallay K, Kassa C, Reti M, et al. Early experience with CliniMACS Prodigy CCS (IFN‐gamma) System in selection of virus‐specific T cells from third‐party donors for pediatric patients with severe viral infections after hematopoietic stem cell transplantation. J Immunother. 2018;41(3):158‐163. doi:10.1097/CJI.0000000000000197
Jiang W, Clancy LE, Avdic S, et al. Third‐party CMV‐ and EBV‐specific T‐cells for first viral reactivation after allogeneic stem cell transplant. Blood Adv. 2022;6(17):4949‐4966. doi:10.1182/bloodadvances.2022007103
Prockop SE, Hasan A, Doubrovina E, et al. Third‐party cytomegalovirus‐specific T cells improved survival in refractory cytomegalovirus viremia after hematopoietic transplant. J Clin Invest. 2023;133(10):e165476. doi:10.1172/JCI165476
Bonifacius A, Lamottke B, Tischer‐Zimmermann S, et al. Patient‐tailored adoptive immunotherapy with EBV‐specific T cells from related and unrelated donors. J Clin Invest. 2023;133(12):e163548. doi:10.1172/JCI163548
Robin C, Thiebaut A, Alain S, et al. Letermovir for secondary prophylaxis of cytomegalovirus infection and disease after allogeneic hematopoietic cell transplantation: results from the French Compassionate Program. Biol Blood Marrow Transplant. 2020;26(5):978‐984. doi:10.1016/j.bbmt.2020.01.027
Styczynski J, Tridello G, Xhaard A, et al. Use of letermovir in off‐label indications: Infectious Diseases Working Party of European Society of Blood and Marrow Transplantation retrospective study. Bone Marrow Transplant. 2021;56(5):1171‐1179. doi:10.1038/s41409‐020‐01166‐w
Leen AM, Bollard CM, Mendizabal AM, et al. Multicenter study of banked third‐party virus‐specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013;121(26):5113‐5123. doi:10.1182/blood‐2013‐02‐486324
Tzannou I, Papadopoulou A, Naik S, et al. Off‐the‐shelf virus‐specific T cells to treat BK virus, Human Herpesvirus 6, Cytomegalovirus, Epstein‐Barr virus, and Adenovirus infections after allogeneic hematopoietic stem‐cell transplantation. J Clin Oncol. 2017;35(31):3547‐3557. doi:10.1200/JCO.2017.73.0655
Mahadeo KM, Baiocchi RA, Beitinjaneh A, et al. New and updated results from a multicenter, open‐label, global Phase 3 study of tabelecleucel (Tab‐cel) for Epstein‐Barr Virus‐positive post‐transplant lymphoproliferative disease (EBV+ PTLD) following allogeneic hematopoietic cell (HCT) or solid organ transplant (SOT) after failure of rituximab or rituximab and chemotherapy (ALLELE). Blood. 2022;140(Supplement 1):10374‐10376. doi:10.1182/blood‐2022‐157766
Haque T, Wilkie GM, Jones MM, et al. Allogeneic cytotoxic T‐cell therapy for EBV‐positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood. 2007;110(4):1123‐1131. doi:10.1182/blood‐2006‐12‐063008
Prockop S, Doubrovina E, Suser S, et al. Off‐the‐shelf EBV‐specific T cell immunotherapy for rituximab‐refractory EBV‐associated lymphoma following transplantation. J Clin Invest. 2020;130(2):733‐747. doi:10.1172/JCI121127
Brestrich G, Zwinger S, Fischer A, et al. Adoptive T‐cell therapy of a lung transplanted patient with severe CMV disease and resistance to antiviral therapy. Am J Transplant. 2009;9(7):1679‐1684. doi:10.1111/j.1600‐6143.2009.02672.x
Holmes‐Liew CL, Holmes M, Beagley L, et al. Adoptive T‐cell immunotherapy for ganciclovir‐resistant CMV disease after lung transplantation. Clin Transl Immunol. 2015;4(3):e35. doi:10.1038/cti.2015.5
Pierucci P, Malouf M, Glanville AR, Beagley L, Smith C, Khanna R. Novel autologous T‐cell therapy for drug‐resistant cytomegalovirus disease after lung transplantation. J Heart Lung Transplant. 2016;35(5):685‐687. doi:10.1016/j.healun.2015.12.031
Smith C, Beagley L, Rehan S, et al. Autologous adoptive T‐cell therapy for recurrent or drug‐resistant cytomegalovirus complications in solid organ transplant recipients: a single‐arm open‐label Phase I clinical trial. Clin Infect Dis. 2019;68(4):632‐640. doi:10.1093/cid/ciy549
Macesic N, Langsford D, Nicholls K, et al. Adoptive T cell immunotherapy for treatment of ganciclovir‐resistant cytomegalovirus disease in a renal transplant recipient. Am J Transplant. 2015;15(3):827‐832. doi:10.1111/ajt.13023
Miele M, Gallo A, Di Bella M, et al. Successful use of heterologous CMV‐reactive T lymphocyte to treat severe refractory cytomegalovirus (CMV) infection in a liver transplanted patient: correlation of the host antiviral immune reconstitution with CMV viral load and CMV miRNome. Microorganisms. 2021;9(4):684. doi:10.3390/microorganisms9040684
Anand M, Nysather J, McGraw G, et al. Viral specific T cell therapy in kidney transplant recipients—a single‐center experience. Transpl Infect Dis. 2023;25(6):e14179. doi:10.1111/tid.14179